TRANSLATING BIOLOGICAL INSIGHTS INTO INNOVATIVE THERAPIES
Praxis Bioresearch is a privately held biopharmaceutical company focused on developing novel therapeutic approaches for neurological conditions, specifically targeting ADHD and apathy in Alzheimer's Disease.
PRX-P4-003: Our Lead Development Candidate
PRX-P4-003 is an innovative oral prodrug designed to selectively deliver (-)-fencamfamine, the active isomer of fencamfamine. This unique compound is expected to combine the best properties of current ADHD treatments: robust dopamine reuptake inhibition (like methylphenidate) with mild dopamine release (like amphetamine), while offering extended duration of action and no monoamine oxidase inhibition. This balanced therapeutic profile with built-in abuse deterrence represents a promising advance in ADHD treatment.
Potential to be first Schedule IV stimulant alternative in ADHD, offering improved safety, efficacy and easier access than current Schedule II stimulants.
- Activated by pancreatic lipase in the gut
- Once-a-day oral dosing (~15 hours duration)
- Built-in abuse deterrence due to gut specific activation mechanism
- "Composition of Matter" patents with PTE to early 2040's
- Potentially alleviating stimulant therapy challenges
PRX-P4-003 activation mechanism
Addressing Critical Patient Needs
People affected globally by ADHD and apathy in AD
- 144-160M children with ADHD worldwide
- 201.5M adults affected by ADHD globally
- 22-34M people with apathy in AD worldwide
First novel stimulant alternative in 4 decades
- Unique balanced mechanism
- Enhanced safety profile
- Once-daily convenience
Potential first approved therapy for apathy in AD
- No currently approved treatments
- Affects 40-60% of AD patients globally
- Growing to 55-70M patients by 2050
Led by Experienced Leadership
Our team brings decades of combined experience in neuroscience, drug development, and clinical research.
With additional guidance from leading experts including Prof. Valentino Stella (Inventor and Prodrug Expert) and Adam Levy (Director, CFO of Mineralys).
Forward-Looking Statements
This website contains forward-looking statements that involve risks and uncertainties, including statements regarding Praxis Bioresearch's research, development, and business plans. Such forward-looking statements are based on Praxis's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the impact of general economic conditions, the success of Praxis's research and development activities, competition from other biopharmaceutical companies, challenges associated with obtaining regulatory approvals, Praxis's ability to obtain additional funding for operations, and the other risks described in Praxis's communications.
All visualizations, animations, and graphical representations on this website, including molecular and biological processes, are simplified visualizations based on available scientific data and expert interpretation. These are intended for illustrative purposes only and should not be considered as exact molecular or biological recreations.
Praxis Bioresearch undertakes no duty or obligation to update any forward-looking statements contained in this website as a result of new information, future events or changes in its expectations. This disclaimer applies to all content across all pages of this website.